Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10052)	4/10/2018 1:37:16 PM
From: HardToFind	Respond to of 12873

In summary: If management try (or tried) to add another (new) herpes drug candidate at this point...it will take (or would have taken) a while. So I don't think it happened. If they are trying to pursue two or three indications rather than just shingles in upcoming human trials, that will delay the start of human trials by at least 9 months (and more likely 18 months or more). I would not put it beyond management to do this, even though it could cause a serious hit to the share price for an equity raise. I'm hoping they will go forward with human trials using just one drug for just one indication (shingles). Taking a second drug through formal tox testing (small and large animals) would cost in the neighborhood of an additional $500K, so it's not a totally unreasonable possibility.